The protocol at a glance
No human dose of injected NAD+ is established. The closest registered trial uses an injectable form of nicotinamide riboside (NR), not NAD+ itself.
| Item | What is known |
|---|---|
| Human dose of NAD+ injection | Not established |
| NR injection trial (NCT07251608) | 50 or 100 mg under the skin, daily for 3 days, then 3 times a week from day 10 to 100 |
| IV NAD+ trials (China, registered) | Once a day for 7 days in children with weak hearts (NCT07839130); 21 days of infusions after cord blood transplant (NCT06558253). Amounts not read. |
| Oral NR trial | Taken by mouth for 6 weeks in older adults (Martens 2018) |
The NR trial is a safety study of a different molecule, with no results yet. It is the nearest thing to a human injection schedule. Do not treat it as an NAD+ dose.
Community protocols describe small injections under the skin several times a week for a couple of months. This is community talk.
What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.
Mixing
No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.
What the trials found
No human trial shows NAD+ injections slow aging. Closest evidence:
Martens CR et al. Nat Commun 2018 (PubMed 29599478); ClinicalTrials.gov NCT07251608, NCT07839130, NCT06558253.
Side effects
- Safety of NAD+ injection is not well studied. I found no completed trial results for it.
- The NR injection trial is measuring side effects and results are not out yet.
How it works
Cell energy coenzyme
NAD+ is used by cells to turn food into energy. It falls with age. Precursors such as NR raise it in blood.
Injection unknown
It is not clear how much injected NAD+ gets into cells.
Sources
- Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018
- ClinicalTrials.gov NCT07251608 (Niagen Plus, NR injection safety study)
- ClinicalTrials.gov NCT07839130 and NCT06558253 (injectable NAD+ / coenzyme I trials in China)